Breast Cancer

The Major Histocompatibility Complex Class II protein has potential to predict immunotherapy benefit in two types of breast cancer.

Pregnant women who had cancer previously or currently have cancer were more likely to experience comorbidities and in-hospital complications, depending on cancer type.

According to data from the Centers for Disease Control’s (CDC) National Breast and Cervical Cancer Early Detection Program, the total number of cancer screening tests declined 87% for breast cancer and 84% for cervical cancer during April 2020.

The unmet need for personalized follow-up care due to a wide variety of health burdens after treatment needs to be addressed.

Significant updates occurred in women’s health issues while the world was in survival mode.

Missing just 1 screening can lead to significant increase in risk, investigators say.

In honor of International Women’s Day, CURE® compiled some recent news and updates in cancer research that you may have missed.

A team of international researchers partnered with the National Cancer Institute and Mayo Clinic to conduct a research opportunity that led to unexpected findings.

Following the 2020 San Antonio Breast Cancer Symposium, Erika P. Hamilton, MD, and William J. Gradishar, MD, shared their key takeaways and insights from the most impactful data presented during this year’s meeting.

A new study found that the rate of cancer in adolescents and young adults increased by 29/6% between 1973 and 2015.

Merck earned a new indication for pembrolizumab (Keytruda), in combination with chemotherapy, to treat locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC).

Study shows implementing the newly cleared software can slightly improve sensitivity and false negatives.

From OncLive, five experts share their perspectives and opinions on the latest research related to triple-negative breast cancer.

In a recent video from OncLive, Erika P. Hamilton, MD, highlights the initial findings from the ongoing phase 1b/2 LIO-trial in advanced metastatic tumors.

According to new research, women with ductal carcinoma in situ (DCIS) are more than three times as likely to suffer from breast cancer mortality than women in the general population.

Officials from the Food and Drug Administration (FDA) issued a safety alert on Sept. 8 about potential efficacy and safety concerns with Tecentriq in combination with Paclitaxel for breast cancer treatment.

Results from the study showed antitumor activity and safety to be similar to olaparib and durvalumab monotherapy outcomes.

According to the findings, mammograms declined by 89.2% in April of this year.

Findings from a new study by Australian researchers suggest that physical activity should be incorporated into cancer care during and beyond treatment.

The lack of data on the possible connection between race and breast cancer prognosis is what led a group of Mount Sinai researchers to conduct this new multicenter, cross-sectional study.

A study from the Long Island Breast Cancer Study Project (LIBCSP) investigated the association between menopausal hormone therapy (MHT) and mortality outcomes among breast cancer survivors.

New research shows that, when seeking treatment for cancer-related fatigue, breast cancer survivors underutilize recommendations.

The study in the Journal of Clinical Oncology is a follow-up to a study conducted by the same authors to evaluate if pregnancy is safe in breast cancer patients who have hormone-sensitive breast cancer.

According to a new study in the American Journal of Health-System Pharmacy, chemotherapy stewardship programs may result in cost savings to both patient and health systems.

Women with ductal carcinoma in situ (DCIS) may experience higher risk of developing invasive breast cancer (IBC) and of death from breast cancer than the general population, according to new research.

New research shows that, in postmenopausal women undergoing hormone therapy for breast cancer, aromatase inhibitors (AIs) lead to a reduction in climacteric symptoms and significantly improved quality of life.

The review concluded that the highest increase in MD is among current users of HRT, particularly those taking continuous estrogen plus progestin (CEP).

Currently, 38 states and the District of Columbia have enacted dense breast notification (DBN) laws mandating that mammogram results include language informing women of risks related to dense breasts.

Across different drugs and clinical settings, use of PARPi has resulted in a prolonged period without cancer recurrence.

In recent years, the United States has seen a shift in greater awareness of the importance of SDOH and toward a more comprehensive approach to healthcare.